Table 4.

Multivariate analysis for determination of Survival in Glioma patient cohort treated with TMZ therapy status.

Variable	TMZ Therapy			No TMZ Therapy
	HR	95% CI	P-value	HR	95% CI	P-value
Age	1.01	0.97–1.059	0.599	1.05	1.00–1.0	0.036
Gender	0.05	0.004–0.645	0.022	0.24	0.08–0.7	0.014
MGMT Protein Expression	2.02	2.00–5.847	0.040	4.31	2.09–7.0	0.006
MGMT Promoter Methylation	0.76	0.21–2.899	0.029	3.78	1.71–6.8	0.706

HR: Hazard ratio; TMZ: Temozolomide.